Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Melanoma
Results Reported On Novel Vaccine Tested In Mice
April 11th, 2001
ImClone Systems Inc. (IMCL) announced March 26, 2001, positive preclinical findings on its novel recombinant hTRPx3 protein-based melanoma vaccine. The presentation was made at the 92nd Annual Meeting of the American Association for Cancer Research (AACR). Melanoma cells can escape immune recognition by several mechanisms, including loss of antigen expression. To overcome this obstacle, researchers at ImClone Systems developed a novel, chimeric vaccine consisting of human melanoma proteins TRP-1, TRP-2, and tyrosinase. Preclinical findings demonstrated that the vaccine elicited antibody and cellular immune responses in...
Source: Vaccine Weekly (2001-04-11)
|
